Biotech stocks surge on growth and analyst upgrades
6.9 Markets Biotech stocks Kodiak, Edgewise, Adaptive, Spyre, Kiniksa, and Biogen hit new highs, fueled by strong returns, positive trial data, and revenue growth, despite overvaluation concerns.
Kodiak Sciences Inc. reached a 52-week high of $104.26, soaring 443.54% over the past year and delivering a total return of 463%. With a $6.47B market cap, the stock is considered overvalued versus its Fair Value, according to InvestingPro. The surge is attributed to strategic advancements and positive Phase 3 DAYBREAK trial results, prompting H.C. Wainwright to raise its price target to $126 and maintain a Buy rating, citing strong prospects for Zenkuda and KSI-501. Edgewise Therapeutics Inc. also hit a record high of $48.53, up 162.14% year-over-year and 81.5% YTD, with a $5.27B market cap. Despite trading above Fair Value, analysts raised earnings forecasts after positive FDA feedback on EDG-7500, leading Raymond James to set a new $85 price target. Adaptive Biotechnologies Corp. reached a 52-week high of $30.74, up 108.26% YoY, with Q3 revenue up 39% to $83.9M, beating expectations. Spyre Therapeutics Inc. hit a 52-week high of $110.28, returning 361% over the year and holding a $10.44B market cap. Although overvalued, analysts are optimistic about its IBD therapy pipeline. Kiniksa Pharmaceuticals International reached an all-time high of $98.49, with a 145% annual return and 58% revenue growth, driven by strong ARCALYST sales. Biogen Inc. also reached a 52-week high of $258.81, up 65.27% YoY, with Q3 results exceeding expectations and analysts raising price targets.
